TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03185312

Intervention type: DIAGNOSTIC_TEST
Intervention: skin biopsy
Description: Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using VASI score for vitiligo and Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin of patients as well as controls. immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.~Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression.

Intervention type: DIAGNOSTIC_TEST
Intervention: skin biopsy
Description: Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using VASI score for vitiligo and Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin of patients as well as controls. immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.~Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression.

Intervention type: DIAGNOSTIC_TEST
Intervention: skin biopsy
Description: Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using VASI score for vitiligo and Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin of patients as well as controls. immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.~Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression.
Study: NCT01570062

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEPA Filter
Description: Two HEPA filters will be placed in participant's homes (one in the bedroom and one in the main living area); each HEPA will run for 2 consecutive 7-day sampling sessions. During one of the 7-day sampling sessions, the HEPA filter will run without the internal filter in place (i.e., placebo filtration).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HEPA Filtration Placebo
Description: for one of the two 7-day sampling sessions, both HEPA filters placed in participants' homes will be run without the actual filter in the housing unit.
Study: NCT02394223

Intervention type: PROCEDURE
Intervention: Full Field Optical Coherence Tomography (FFOCT) procedure
Description: TRUS Prostate biopsy are performed under the care procedure Pathological examination of these prostate biopsy with FFOCT procedure, as compared to standard pathological evaluation
Study: NCT04261881

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ATP-Fuel
Description: 5 capsules daily with breakfast and 5 capsules daily with lunch

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ATP-II
Description: 3 capsules daily with breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ATP-II
Description: 3 capsules daily with breakfast and 3 capsules daily with lunch
Study: NCT03274245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Package
Description: * Community Level:~  * Palla: songs and skits to increase knowledge of and motivation for latrine use, pit emptying, safe feces disposal;~ * Transect Walk: village walk to identify and mark feces in community;~ * Community meetings: sex-segregated meetings with village members to decide on an action plan to increase community cleanliness/reduce open defecation;~ * Wall painting: village map noting households that use latrines always.~* Sub-Community level:~  * Mothers meeting: For caregivers with children under age 5, to provide knowledge of and hardware for safe child feces disposal.~* Household Level:~  * Household visits: to those with latrines to motivate use;~ * Latrine repairs: for households with non-functional latrines to make functional.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Package
Description: * Community Level:~  * Palla: songs and skits to increase knowledge of and motivation for latrine use, pit emptying, safe feces disposal;~ * Transect Walk: village walk to identify and mark feces in community;~ * Community meetings: sex-segregated meetings with village members to decide on an action plan to increase community cleanliness/reduce open defecation;~ * Wall painting: village map noting households that use latrines always.~* Sub-Community level:~  * Mothers meeting: For caregivers with children under age 5, to provide knowledge of and hardware for safe child feces disposal.~* Household Level:~  * Household visits: to those with latrines to motivate use;~ * Latrine repairs: for households with non-functional latrines to make functional.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qualitative Research
Description: For villages receiving the intervention package, investigators will engage community members through qualitative interviews to gain their perception of the intervention, what they thought of the intervention activities, what information they recall, what aspects they enjoyed or disliked, if they had barriers to attendance or participation.~For the three villages not receiving the intervention, investigators will conduct qualitative interviews to determine additional barriers and determinants of latrine use to identify other potential intervention strategies.
Study: NCT02150512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transpulmonary Thermodilution
Description: Initial trigger for fluid loading when circulatory insufficiency is present will be SVV. If SVV ≤10% in patients on controlled mechanical ventilation with tidal volumes of ≥8 ml/kg, fluid loading will not be performed. If SVV \>10% or spontaneous breathing efforts are present, a fluid challenge should be performed. Also if patients are on controlled mechanical ventilation with tidal volumes of ≤7 ml/kg, a fluid challenge should be performed. If fluid responsiveness is present and SVV decreases to ≤10%, further fluid loading should be stopped. If SVV is still \>10%, the increase in EVLW will decide whether to continue fluid loading or not; if EVLW is ≥12 mL/kg PBW and EVLW increases upon fluid loading, further fluid loading should be stopped.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surviving Sepsis Guidelines (SSG)
Description: Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg). If circulatory insufficiency is absent, fluid loading will not be initiated or stopped independently of the actual CVP level.
Study: NCT01856803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti thymoglobulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti thymoglobulin
Study: NCT00588757

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optease IVC filters
Description: IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
Study: NCT00186888

Intervention type: OTHER
Group type: OTHER
Intervention: G-CSF
Description: G-CSF (5 mcg/kg/day), will be administered starting 24-36 hours after the completion of each course of chemotherapy, for 7 to 10 days, until ANC is \> 2,000/mL in one occasion after the expected nadir.
Study: NCT00588757

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gunter-Tulip IVC filters
Description: IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
Study: NCT04864600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Candle C
Description: Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Candle 1
Description: Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
Study: NCT01026350

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: colostrum enriched with anti flu antibodies
Description: each volunteer will receive six 1.2 g oral tablets (equivalent to 600 mg of bovine colostrum powder each) once a day for two weeks.
Study: NCT00608881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: coenzyme Q10
Description: 4 - 300 mg CoQ chewable wafers taken orally twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study: NCT04202276

Intervention type: OTHER
Group type: OTHER
Intervention: diet assessment
Description: Food frequency questionnaire to investigate differences in diet of children and adolescents with GERD compared to the age- and sex matched control group.

Intervention type: OTHER
Group type: OTHER
Intervention: diet assessment
Description: Food frequency questionnaire to investigate differences in diet of children and adolescents with GERD compared to the age- and sex matched control group.
Study: NCT03994601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986288
Description: Specified dose on specified days
Study: NCT00761358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-338
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT01382095

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dscCfaE
Description: 50 ug on study days 0, 21 and 42

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dscCfaE
Description: 50 ug on study days 0, 21 and 42

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fimbrial adhesin dscCfaE
Description: 250 ug on study days 0, 21 and 42

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified E. coli heat labile enterotoxin LTR192G
Description: 50 ug on study days 0, 21 and 42

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified E. coli heat labile enterotoxin LTR192G
Description: 50 ug on study days 0, 21 and 42

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified E. coli heat labile enterotoxin LTR192G
Description: 50 ug on study days 0, 21 and 42
Study: NCT04384211

Intervention type: OTHER
Intervention: Computer Assisted Detection Software For Vertebral Fractures
Description: A device named Smart Bone that is using CT image retrospectively acquired to entails a second review of CT images with Vertebral Compression Fractures through an interactive AI program developed by Quanta Computer Inc. was applied to the CT images. The device is a computer-aided detection (CADe) software application and is designed to assist radiologists to analyze Spine CT images. The device uses deep learning methods to perform vertebrae detection and classification of images.
Study: NCT00709930

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic field generator
Description: dosage:Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF frequency:10min/day duration:1 month

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo magnetic field generator
Description: Placebo device with no magnetic fields
Study: NCT02369289

Intervention type: OTHER
Intervention: bone mineral density test

Intervention type: OTHER
Intervention: bone mineral density test
Study: NCT02256254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 2 Simvastatin capsules of 20 mg every evening for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo capsules every evening for 14 days
Study: NCT01637246

Intervention type: DRUG
Intervention: Any Fixed Combination Therapy
Description: Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy. This was a retrospective chart review study, so no treatment was administered in this study.
Study: NCT03750968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carotenoid Group
Description: Softgel active ingredients: Lutein 10 mg and Zeaxanthin 2 mg in safflower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Placebo ingredients: Safflower oil
Study: NCT03218306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical Pleth Index
Description: Effector site concentration of remifentanil based on SPI
Study: NCT03994601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986288
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT03218306

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical guidance
Description: Effector site concentration of remifentanil based on hemodynamic data
Study: NCT06371755

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound examination with REMS technology
Description: The proposed study is defined as interventional because it introduces an ultrasound examination in the standard clinical routine. The diagnostic approach does not vary during the study and the prescription of any therapeutic treatment is performed on the basis of the conventional DXA diagnosis. This ultrasound examination does not involve additional risks for the patient with the benefit of not using ionizing radiation; it lasts only few minutes and can be performed without moving the patient from the same bed on which he is already positioned for DXA examination.
Study: NCT01444183

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle relaxation
Description: Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham exercise
Description: The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria.
Study: NCT02914197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full information
Description: Patients will be randomized to receive full information or standard information at the study start. The second wave will follow the same randomization process 6 months following the study start.
Study: NCT03594461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Intense Treatment Regimen for Refractory Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Intense Treatment Regimen for Refractory Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy
Study: NCT03892525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selicrelumab
Description: escalated dose in intratumoral injection, every 3 weeks, for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200mg IV every 3 week until progression or relapse for maximum 1 year
Study: NCT04061941

Intervention type: BEHAVIORAL
Intervention: Cognitive Assessment
Description: Assessment on cognitive dysfunction using standardised cognitive tests
Study: NCT01230918

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-NC100692
Description: HCM and ACS subjects: 99mTc-NC100692 SPECT scan, CMR and echocardiography images will be obtained and compared.~Normal control: 99mTc-NC100692 SPECT scan, CMR and echocardiography imaging obtained for comparison with HCM and ACS images.
Study: NCT03379441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injectable Product
Description: Pembrolizumab Injectable Product 200 mg Q3W Intravenous
Study: NCT00838695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Intravenous phenylephrine at low doses (approximately 10 doses ranging from 0-5000 ng/min) Intravenous nitroglycerin at low doses (approximately 10 doses ranging from 0.05-100 ng/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Intravenous phenylephrine at low doses (approximately 10 doses ranging from 0-5000 ng/min) Intravenous nitroglycerin at low doses (approximately 10 doses ranging from 0.05-100 ng/min)
Study: NCT00550823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac CT 0BRILLIANT 64
Description: Cardiac CT
Study: NCT04156204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS)
Description: AYA kidney recipients will receive a Medication Event Monitoring System (MEMS) via medication bottle and cap system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once-Daily Tacrolimus extended release
Description: AYA kidney recipients will receive once daily tacrolimus XR 1-10mg daily
Study: NCT01156155

Intervention type: RADIATION
Intervention: Digital xray of jaw and teeth
Description: one time xray of jaw and teeth

Intervention type: RADIATION
Intervention: Digital xray of jaw and teeth
Description: one time xray of jaw and teeth

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Three to four tablespoons of blood drawn.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Three to four tablespoons of blood drawn.

Intervention type: OTHER
Intervention: questionnaires
Description: completed questionnaires regarding patient's health and functional ability.

Intervention type: OTHER
Intervention: questionnaires
Description: completed questionnaires regarding patient's health and functional ability.

Intervention type: PROCEDURE
Intervention: Periodontal Examination
Description: Periodontal examination including measurement of gum pockets with a probe. Bacterial samples taken.

Intervention type: PROCEDURE
Intervention: Periodontal Examination
Description: Periodontal examination including measurement of gum pockets with a probe. Bacterial samples taken.

Intervention type: OTHER
Intervention: Bilateral digital xray of hands
Description: One time digital xray of hands
Study: NCT03988842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Lyophilized powder for reconstitution in 50mg vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: Heparin sodium in 0.45% sodium chloride injection for intravenous use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Heparin sodium in 0.45% sodium chloride injection for intravenous use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline solution reconstituted to mimic Alteplase 50mg vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Apixaban tablet
Study: NCT00308997

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 1-hertz Repetitive Transcranial Magnetic Stimulation
Description: Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active 1-Hertz Repetitive transcranial magnetic stimulation
Description: Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
Study: NCT00979121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.
Study: NCT02891915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin is an aminopenicillin antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin is an aminopenicillin antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefdinir
Description: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefdinir
Description: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03778515

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in patients with Ankylosing Spondylitis (AS).

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in patients with Ankylosing Spondylitis (AS).
Study: NCT01289314

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TLH
Description: Total laparoscopic hysterectomy (TLH)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy
Description: Laparoscopic supracervical hysterectomy (LSH)